DARA Share Price

Open 0.00 Change Price %
High 0.95 1 Day 0.00 0.00
Low 0.88 1 Week 0.00 0.00
Close 0.88 1 Month 0.00 0.00
Volume 391218 1 Year 0.00 0.00
52 Week High 11.12
52 Week Low 6.34
DARA Important Levels
Resistance 2 0.94
Resistance 1 0.92
Pivot 0.90
Support 1 0.84
Support 2 0.82
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ASTI 0.00 0.00%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
TEAR 3.34 89.77%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TOPS 0.26 23.81%
BONT 0.80 17.65%
HAUP 0.07 16.67%
PLUG 2.44 15.09%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

DARA Biosciences, Inc. (NASDAQ: DARA)

DARA Technical Analysis 3
As on 4th Dec 2015 DARA Share Price closed @ 0.88 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.85 & Buy for SHORT-TERM with Stoploss of 0.86 we also expect STOCK to react on Following IMPORTANT LEVELS.
DARA Target for July
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
DARA Other Details
Segment EQ
Market Capital 11975324.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.darabiosciences.com
DARA Address
DARA
8601 Six Forks Road
Suite 160
Raleigh, NC 27615
United States
Phone: 919-872-5578
Fax: 919-861-0239
DARA Latest News
Interactive Technical Analysis Chart DARA Biosciences, Inc. ( DARA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on DARA Biosciences, Inc.
DARA Business Profile
DARA BioSciences, Inc. is a specialty pharmaceutical company primarily focused on the commercialization of oncology treatment and oncology supportive care pharmaceutical products. The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy (CCIPN). Its primary focus is on the commercialization of the oncology treatment and oncology supportive care pharmaceutical products, which include Soltamox, Cancer support therapeutics and Three Mission Pharmacal products. The Company�s oral liquid products can provide a alternative to solid dose formulations for those patients with dysphagia, or difficulty swallowing, or those who simply prefer to take drug products in liquid form.